Categories Earnings, LATEST, Technology, U.S. Markets News

Infosys misses Q1 earnings estimates; maintains FY19 outlook

Software services company Infosys (INFY) reported a marginal decline in its earnings for the first quarter of 2019, missing the consensus estimates, while revenue numbers met expectations. Profit for the quarter came in at $534 million, down 1.2% year-over-year. However, profit on a per share basis, grew 3.9% to $0.25 per share. Net profit included an impact of $39 million for the reduction in the fair value of assets held for sale.

Revenue grew 6.8% to $2.83 million for the quarter, driven by growth in the company’s digital business offerings and higher deal wins in Q1. On a geographic basis, Europe and Rest of World posted marginal growth in revenue, while North America and India posted declines.

The Bengaluru, India based software giant also said that its deal wins crossed $1 billion, of which over 40% were from Financial Services.

Infosys Limited first quarter 2019 earnings

Additionally, the company’s Board appointed Michael Gibbs as an Independent Director effective today for a period of three years, based on the recommendation of the Nomination and Remuneration Committee of the Board.

Infosys board also today issued a 1:1 bonus of equity shares and a 1:1 stock dividend of American depository shares. The company said the bonus shares were issued to celebrate the 25th year of its public listing in India and to increase the liquidity of its shares further.

Related: Infosys posts strong Q4 results, beats expectations

For the fiscal year 2019, Infosys retained its revenue guidance in constant currency at 6% to 8% and operating margin guidance was retained at 22% to 24%.

Post the earnings announcement, Infosys stock slumped more than 4% pre-market trading, while the stock had a stellar run during the past one year, jumping more than 30%.

Related: Q4 earnings snapshot

Infosys earnings graphic

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top